180 related articles for article (PubMed ID: 21204907)
1. Evaluation of sulfonamide detoxification pathways in haematologic malignancy patients prior to intermittent trimethoprim-sulfamethoxazole prophylaxis.
Abouraya M; Sacco JC; Kahl BS; Trepanier LA
Br J Clin Pharmacol; 2011 Apr; 71(4):566-74. PubMed ID: 21204907
[TBL] [Abstract][Full Text] [Related]
2. Combined ascorbate and glutathione deficiency leads to decreased cytochrome b5 expression and impaired reduction of sulfamethoxazole hydroxylamine.
Bhusari S; Abouraya M; Padilla ML; Pinkerton ME; Drescher NJ; Sacco JC; Trepanier LA
Arch Toxicol; 2010 Aug; 84(8):597-607. PubMed ID: 20221587
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of trimethoprim/sulfamethoxazole in a macaque model of HIV infection.
Wong YY; Rakasz EG; Gasper DJ; Friedrich TC; Trepanier LA
Toxicology; 2016 Aug; 368-369():10-18. PubMed ID: 27565715
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of N-acetylcysteine for prevention of trimethoprim-sulfamethoxazole hypersensitivity reactions in Pneumocystis carinii pneumonia prophylaxis (CTN 057). Canadian HIV Trials Network 057 Study Group.
Walmsley SL; Khorasheh S; Singer J; Djurdjev O
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(5):498-505. PubMed ID: 9859964
[TBL] [Abstract][Full Text] [Related]
5. Successful outpatient graded administration of trimethoprim-sulfamethoxazole in patients without HIV and with a history of sulfonamide adverse drug reaction.
Pyle RC; Butterfield JH; Volcheck GW; Podjasek JC; Rank MA; Li JT; Harish A; Poe KL; Park MA
J Allergy Clin Immunol Pract; 2014; 2(1):52-8. PubMed ID: 24565769
[TBL] [Abstract][Full Text] [Related]
6. A comparison of adverse drug reactions between high- and standard-dose trimethoprim-sulfamethoxazole in the ambulatory setting.
Nguyen AT; Gentry CA; Furrh RZ
Curr Drug Saf; 2013 Apr; 8(2):114-9. PubMed ID: 23713542
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the clinical, immunologic, and biochemical effects of nitroso sulfamethoxazole administration to dogs: a pilot study.
Lavergne SN; Volkman EM; Maki JE; Yoder AR; Trepanier LA
Toxicology; 2005 Mar; 208(1):63-72. PubMed ID: 15664433
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome b5 and NADH cytochrome b5 reductase: genotype-phenotype correlations for hydroxylamine reduction.
Sacco JC; Trepanier LA
Pharmacogenet Genomics; 2010 Jan; 20(1):26-37. PubMed ID: 19997042
[TBL] [Abstract][Full Text] [Related]
9. Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients.
Urbancic KF; Pisasale D; Wight J; Trubiano JA
Transpl Infect Dis; 2018 Dec; 20(6):e12968. PubMed ID: 30030892
[TBL] [Abstract][Full Text] [Related]
10. The association of opportunistic infections with the occurrence of trimethoprim/sulfamethoxazole hypersensitivity in patients infected with human immunodeficiency virus.
Lehmann DF; Liu A; Newman N; Blair DC
J Clin Pharmacol; 1999 May; 39(5):533-7. PubMed ID: 10234602
[TBL] [Abstract][Full Text] [Related]
11. Roles of endogenous ascorbate and glutathione in the cellular reduction and cytotoxicity of sulfamethoxazole-nitroso.
Lavergne SN; Kurian JR; Bajad SU; Maki JE; Yoder AR; Guzinski MV; Graziano FM; Trepanier LA
Toxicology; 2006 May; 222(1-2):25-36. PubMed ID: 16473451
[TBL] [Abstract][Full Text] [Related]
12. Safety of dapsone as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole.
Beumont MG; Graziani A; Ubel PA; MacGregor RR
Am J Med; 1996 Jun; 100(6):611-6. PubMed ID: 8678080
[TBL] [Abstract][Full Text] [Related]
13. Successful prophylaxis of Pneumocystis carinii pneumonia with trimethoprim-sulfamethoxazole in AIDS patients with previous allergic reactions.
Shafer RW; Seitzman PA; Tapper ML
J Acquir Immune Defic Syndr (1988); 1989; 2(4):389-93. PubMed ID: 2526871
[TBL] [Abstract][Full Text] [Related]
14. Role of Oxidative Stress in Hypersensitivity Reactions to Sulfonamides.
Elzagallaai AA; Sultan EA; Bend JR; Abuzgaia AM; Loubani E; Rieder MJ
J Clin Pharmacol; 2020 Mar; 60(3):409-421. PubMed ID: 31709574
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic antibiotics for the prevention of early infection in multiple myeloma.
Oken MM; Pomeroy C; Weisdorf D; Bennett JM
Am J Med; 1996 Jun; 100(6):624-8. PubMed ID: 8678082
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy evaluation of low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis pneumonia in HIV uninfected patients undergoing hemodialysis: a retrospective observational study.
Yamashita K; Shimomura Y; Ikesue H; Muroi N; Yoshimoto A; Hashida T
BMC Infect Dis; 2021 Jul; 21(1):664. PubMed ID: 34238239
[TBL] [Abstract][Full Text] [Related]
17. Hyponatremia and/or hyperkalemia in patients treated with the standard dose of trimethoprim-sulfamethoxazole.
Mori H; Kuroda Y; Imamura S; Toyoda A; Yoshida I; Kawakami M; Tabei K
Intern Med; 2003 Aug; 42(8):665-9. PubMed ID: 12924488
[TBL] [Abstract][Full Text] [Related]
18. Cross-reactivity between darunavir and trimethoprim-sulfamethoxazole in HIV-infected patients.
Buijs BS; van den Berk GE; Boateng CP; Hoepelman AI; van Maarseveen EM; Arends JE
AIDS; 2015 Apr; 29(7):785-91. PubMed ID: 25985401
[TBL] [Abstract][Full Text] [Related]
19. Monitoring adverse drug reactions to sulfonamide antibiotics in human immunodeficiency virus-infected individuals.
Neuman MG; Malkiewicz IM; Phillips EJ; Rachlis AR; Ong D; Yeung E; Shear NH
Ther Drug Monit; 2002 Dec; 24(6):728-36. PubMed ID: 12451289
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of rechallenge with low-dose trimethoprim-sulphamethoxazole in previously hypersensitive HIV-infected patients.
Carr A; Penny R; Cooper DA
AIDS; 1993 Jan; 7(1):65-71. PubMed ID: 8442919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
